Deciphera Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Deciphera Pharmaceuticals' es Steve Hoerter , nombrado en Mar 2019, tiene una permanencia de 5.08 años. compensación anual total es $3.55M, compuesta por 19.8% salario y 80.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.089% de las acciones de la empresa, por valor de €992.44K. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 8.8 años, respectivamente.

Información clave

Steve Hoerter

Chief Executive Officer (CEO)

US$6.0m

Compensación total

Porcentaje del salario del CEO	12.3%
Permanencia del CEO	5.2yrs
Participación del CEO	0.09%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	8.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve Hoerter en comparación con los beneficios de Deciphera Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$6m	US$738k	-US$195m
Sep 30 2023	n/a	n/a	-US$194m
Jun 30 2023	n/a	n/a	-US$187m
Mar 31 2023	n/a	n/a	-US$182m
Dec 31 2022	US$4m	US$703k	-US$179m
Sep 30 2022	n/a	n/a	-US$221m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$286m
Dec 31 2021	US$9m	US$676k	-US$300m
Sep 30 2021	n/a	n/a	-US$274m
Jun 30 2021	n/a	n/a	-US$258m
Mar 31 2021	n/a	n/a	-US$255m
Dec 31 2020	US$8m	US$650k	-US$266m
Sep 30 2020	n/a	n/a	-US$271m
Jun 30 2020	n/a	n/a	-US$263m
Mar 31 2020	n/a	n/a	-US$218m
Dec 31 2019	US$9m	US$435k	-US$192m
Sep 30 2019	n/a	n/a	-US$157m
Jun 30 2019	n/a	n/a	-US$126m
Mar 31 2019	n/a	n/a	-US$126m
Dec 31 2018	US$447k	n/a	-US$100m

Compensación vs. Mercado: La compensación total de Steve($USD3.55M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.63M).

Compensación vs. Ingresos: La compensación de Steve ha aumentado mientras la empresa no es rentable.

CEO

Steve Hoerter (52 yo)

5.2yrs

Permanencia

US$6,010,712

Compensación

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Hoerter	President	5.2yrs	US$6.01m	0.088% $ 1.7m
Thomas Kelly	Executive VP	9.3yrs	US$2.03m	0.052% $ 1.0m
Dashyant Dhanak	Executive VP & Chief Scientific Officer	less than a year	US$3.06m	0% $ 0
Daniel Martin	Senior VP & Chief Commercial Officer	5.7yrs	US$1.58m	0.038% $ 738.6k
Matthew Sherman	Executive VP & Chief Medical Officer	4.6yrs	US$2.13m	0.088% $ 1.7m
Kevin Brodbeck	Senior VP & Chief Technical Officer	less than a year	sin datos	sin datos
Jennifer Larson	Senior Vice President of Finance & Investor Relations	no data	sin datos	sin datos
Jeffrey Held	Senior VP & General Counsel	5.2yrs	sin datos	sin datos
Lisa Price	Senior VP & Chief Human Resources Officer	2.3yrs	sin datos	sin datos
Jama Pitman	Senior VP & Chief Development Officer	4.3yrs	sin datos	0.042% $ 807.2k
Margarida Duarte	Senior VP & Head of International	3.3yrs	sin datos	sin datos
Rodrigo Soto	Senior Vice President of Clinical Development	3.3yrs	sin datos	sin datos

4.3yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de D05 se considera experimentado (4.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Hoerter	President	6yrs	US$6.01m	0.088% $ 1.7m
John Martin	Independent Director	9.3yrs	US$388.59k	0% $ 0
Edward Benz	Independent Director	7.6yrs	US$396.09k	0% $ 0
Patricia L. Allen	Independent Director	7.7yrs	US$398.55k	0% $ 0
Ron Squarer	Independent Chairman	4.4yrs	US$403.30k	0% $ 0
Jean-Yves Blay	Member of Scientific Advisory Board	8.9yrs	sin datos	sin datos
James Bristol	Independent Director	16.8yrs	US$414.77k	0% $ 0
John Condeelis	Member of Scientific Advisory Board	no data	sin datos	sin datos
Filip Janku	Member of Scientific Advisory Board	8.9yrs	sin datos	sin datos
F. Hodi	Member of Scientific Advisory Board	8.9yrs	sin datos	sin datos
Dennis Walsh	Independent Director	9.3yrs	US$386.05k	0.013% $ 259.4k
John de Groot	Member of Scientific Advisory Board	no data	sin datos	sin datos

8.9yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de D05 se considera experimentada (8.8 años de antigüedad promedio).

Deciphera Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

President recently sold €437k worth of stock

Senior VP & Chief Commercial Officer recently sold €205k worth of stock

President recently sold €244k worth of stock

President recently sold €244k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Recent updates

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Full year 2023 earnings released: US$2.29 loss per share (vs US$2.37 loss in FY 2022)

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold €437k worth of stock

Senior VP & Chief Commercial Officer recently sold €205k worth of stock

President recently sold €244k worth of stock

President recently sold €244k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings released: US$0.58 loss per share (vs US$0.55 loss in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: US$0.57 loss per share (vs US$0.60 loss in 2Q 2022)

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Now 22% undervalued after recent price drop

Independent Director recently bought €139k worth of stock

First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$2.37 loss per share (vs US$5.16 loss in FY 2021)

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Now 21% undervalued

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

Insufficient new directors

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.37 loss in 3Q 2021)

Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$1.22 loss in 2Q 2021)

Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

First quarter 2022 earnings released: US$0.80 loss per share (vs US$1.06 loss in 1Q 2021)

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Insufficient new directors

Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting

Insufficient new directors

Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022

Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Third quarter 2021 earnings released: US$1.37 loss per share (vs US$1.13 loss in 3Q 2020)

Executive VP & Chief Medical Officer recently sold €76k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Second quarter 2021 earnings released: US$1.22 loss per share (vs US$1.20 loss in 2Q 2020)

Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene

Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

First quarter 2021 earnings released: US$1.06 loss per share (vs US$1.36 loss in 1Q 2020)

New 90-day low: €34.40

Full year 2020 earnings released: US$4.78 loss per share (vs US$4.49 loss in FY 2019)

Revenue beats expectations

Deciphera Pharmaceuticals, Inc. Announces Appointment of Margarida Duarte as Senior Vice President, Head of International

Deciphera Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 09, 2021

New 90-day low: €38.20

New 90-day low: €43.00

Deciphera Pharmaceuticals, Inc. Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor

New 90-day high: €54.50

Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting

Revenue beats expectations

Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize Qinlock (Ripretinib)

Specialised Therapeutics Asia Signs an Agreement with Deciphera Pharmaceuticals, Inc. to Commercialise the Switch-Control Tyrosine Kinase Inhibitor QINLOCK (ripretinib)

Deciphera Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: €52.50

New 90-day high: €48.20

Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology Virtual Congress 2020